Protolabs Reports Financial Results for the Third Quarter of 2023
- Proto Labs achieved record revenue in the third quarter, demonstrating the success of its hybrid model combining the digital factory and the digital network.
- Revenue for the quarter increased by 7.4% compared to the same period last year, reaching $130.7 million.
- The digital network, powered by Hubs, experienced significant growth, with revenue of $22.6 million, up 86.9% YoY.
- Gross margin improved to 45.4% in Q3 2023, compared to 43.4% in Q2 2023.
- EBITDA increased to $19.5 million, representing 14.9% of revenue, compared to $11.4 million in Q2 2023.
- Cash flow from operations was $24.2 million in Q3 2023, compared to $9.3 million in Q2 2023.
- The company repurchased $9.0 million of shares during the quarter, and cash and investments balance was $114.9 million as of September 30, 2023.
- None.
Record Revenue of
Record Network Revenue of
GAAP Earnings Per Share of
Third Quarter 2023 Highlights:
-
Revenue for the third quarter of 2023 was a record
, representing a$130.7 million 7.4% increase over the third quarter of 2022. -
Revenue generated from the digital network, powered by Hubs, was
in the third quarter, representing growth of$22.6 million 86.9% over the third quarter of the prior year. -
Net income for the third quarter of 2023 was
, or$8.0 million per diluted share.$0.31 -
Non-GAAP net income was
, or$13.2 million per diluted share. See “Non-GAAP Financial Measures” below.$0.51
"Protolabs produced third quarter financial results that surpassed our expectations on the top and bottom line. We generated record revenue, improved profitability, generated substantial cash flow, and returned capital to shareholders." said Rob Bodor, President and Chief Executive Officer. "This excellent financial performance demonstrates the success of our strategy; Protolabs' unique hybrid model combining the digital factory and the digital network is the best way to grow profitably in our industry. We experienced increased demand for our comprehensive digitally-enabled manufacturing capabilities in the quarter. The model is winning and customers are delighted."
Additional Third Quarter 2023 Highlights:
- Protolabs served 23,080 unique product developers during the quarter.
-
Gross margin was
45.4% in the third quarter of 2023, up sequentially from43.4% in the second quarter of 2023. -
Non-GAAP gross margin was
46.0% in the third quarter of 2023, representing a sequential increase of 190 basis points. See “Non-GAAP Financial Measures” below. -
EBITDA was
, or$19.5 million 14.9% of revenue, in the third quarter of 2023, compared to , or$11.4 million 9.3% of revenue, in the second quarter of 2023. See “Non-GAAP Financial Measures” below. -
Adjusted EBITDA was
, or$23.9 million 18.3% of revenue, in the third quarter of 2023, compared to , or$19.2 million 15.7% of revenue, in the second quarter of 2023. See “Non-GAAP Financial Measures” below. -
Cash flow from operations was
in the third quarter of 2023, compared to$24.2 million in the second quarter of 2023.$9.3 million -
The Company repurchased
of shares during the quarter.$9.0 million -
Cash and investments balance was
as of September 30, 2023.$114.9 million
"Along with record revenue in the third quarter, we made substantial progress on our priority to improve profitability in both the digital factory and the digital network," said Dan Schumacher, Chief Financial Officer. "Through a challenging macro environment, Protolabs has demonstrated the industry-leading earnings power and cash flow generation of our business model, enabling us to continue to invest in future growth and return capital to shareholders."
Non-GAAP Financial Measures
The Company has included non-GAAP revenue growth by region and by service line that excludes the impact of changes in foreign currency exchange rates (collectively, “non-GAAP revenue growth”). Management believes these metrics, when viewed in conjunction with the comparable GAAP metrics, are useful in evaluating the underlying business trends and ongoing operating performance of the Company.
The Company has included earnings before interest, taxes, depreciation and amortization (“EBITDA”) and EBITDA, adjusted for stock-based compensation expense, unrealized (gain) loss on foreign currency and costs related to the
The Company has included non-GAAP gross margin, adjusted for stock-based compensation expense and amortization expense in this press release to provide investors with additional information regarding the Company’s financial results.
The Company has included non-GAAP operating margin, adjusted for stock-based compensation expense, amortization expense and costs related to the closure of
The Company has included non-GAAP gross margin excluding
The Company has included non-GAAP net income, adjusted for stock-based compensation expense, amortization expense, unrealized (gain) loss on foreign currency and costs related to the closure of
The Company has provided below reconciliations of GAAP to non-GAAP net income, non-GAAP gross margin, non-GAAP gross margin excluding
Conference Call
The Company has scheduled a conference call to discuss its third quarter 2023 financial results and fourth quarter 2023 outlook today, November 3, 2023 at 8:30 a.m. EDT. To access the call in the
About Protolabs
Protolabs is the fastest and most comprehensive digital manufacturing service in the world. Our digital factories produce low-volume parts in days while our digital network of manufacturing partners powered by Hubs unlocks advanced capabilities and volume pricing at higher quantities. The result? One manufacturing source—from prototyping to production—for product developers, engineers, and supply chain teams across the globe. See what's next at protolabs.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical or current facts are “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties and other factors which may cause the results of Protolabs to be materially different than those expressed or implied in such statements. Certain of these risk factors and others are described in the “Risk Factors” section within reports filed with the SEC. Other unknown or unpredictable factors also could have material adverse effects on Protolabs’ future results. The forward-looking statements included in this press release are made only as of the date hereof. Protolabs cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, Protolabs expressly disclaims any intent or obligation to update any forward-looking statements to reflect subsequent events or circumstances.
Proto Labs, Inc. Condensed Consolidated Balance Sheets (In thousands) |
|||||
|
|
|
|
||
|
September 30,
|
|
December 31,
|
||
|
(Unaudited) |
|
|
||
Assets |
|
|
|
||
Current assets |
|
|
|
||
Cash and cash equivalents |
$ |
83,496 |
|
$ |
56,558 |
Short-term marketable securities |
|
19,204 |
|
|
23,568 |
Accounts receivable, net |
|
78,395 |
|
|
76,225 |
Inventory |
|
13,803 |
|
|
13,578 |
Income taxes receivable |
|
891 |
|
|
4,042 |
Prepaid expenses and other current assets |
|
8,722 |
|
|
12,597 |
Total current assets |
|
204,511 |
|
|
186,568 |
|
|
|
|
||
Property and equipment, net |
|
243,022 |
|
|
257,785 |
Goodwill |
|
273,991 |
|
|
273,991 |
Other intangible assets, net |
|
26,668 |
|
|
31,250 |
Long-term marketable securities |
|
12,212 |
|
|
26,419 |
Operating lease assets |
|
2,737 |
|
|
3,844 |
Finance lease assets |
|
16,763 |
|
|
17,532 |
Other long-term assets |
|
4,341 |
|
|
4,779 |
Total assets |
$ |
784,245 |
|
$ |
802,168 |
|
|
|
|
||
Liabilities and shareholders' equity |
|
|
|
||
Current liabilities |
|
|
|
||
Accounts payable |
$ |
17,922 |
|
$ |
17,356 |
Accrued compensation |
|
16,337 |
|
|
12,743 |
Accrued liabilities and other |
|
21,027 |
|
|
22,384 |
Current operating lease liabilities |
|
1,568 |
|
|
1,561 |
Current finance lease liabilities |
|
16,630 |
|
|
17,537 |
Income taxes payable |
|
1,144 |
|
|
— |
Total current liabilities |
|
74,628 |
|
|
71,581 |
|
|
|
|
||
Long-term operating lease liabilities |
|
1,545 |
|
|
2,255 |
Long-term finance lease liabilities |
|
671 |
|
|
— |
Long-term deferred tax liabilities |
|
17,138 |
|
|
26,322 |
Other long-term liabilities |
|
5,341 |
|
|
4,362 |
|
|
|
|
||
Shareholders' equity |
|
684,922 |
|
|
697,648 |
Total liabilities and shareholders' equity |
$ |
784,245 |
|
$ |
802,168 |
|
|
|
|
||
|
|
|
|
Proto Labs, Inc. Condensed Consolidated Statements of Operations (In thousands, except share and per share amounts) (Unaudited) |
||||||||||||||
|
|
|
|
|
|
|
|
|||||||
|
Three Months Ended
|
|
Nine Months Ended
|
|||||||||||
|
|
2023 |
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
Revenue |
|
|
|
|
|
|
|
|||||||
Injection Molding |
$ |
51,688 |
|
$ |
48,940 |
|
|
$ |
152,455 |
|
|
$ |
155,693 |
|
CNC Machining |
|
52,916 |
|
|
47,489 |
|
|
|
149,317 |
|
|
|
141,809 |
|
3D Printing |
|
21,622 |
|
|
19,823 |
|
|
|
63,952 |
|
|
|
59,458 |
|
Sheet Metal |
|
4,291 |
|
|
5,219 |
|
|
|
12,478 |
|
|
|
15,066 |
|
Other Revenue |
|
188 |
|
|
250 |
|
|
|
627 |
|
|
|
765 |
|
Total Revenue |
|
130,705 |
|
|
121,721 |
|
|
|
378,829 |
|
|
|
372,791 |
|
|
|
|
|
|
|
|
|
|||||||
Cost of revenue |
|
71,423 |
|
|
68,089 |
|
|
|
212,648 |
|
|
|
205,933 |
|
Gross profit |
|
59,282 |
|
|
53,632 |
|
|
|
166,181 |
|
|
|
166,858 |
|
|
|
|
|
|
|
|
|
|||||||
Operating expenses |
|
|
|
|
|
|
|
|||||||
Marketing and sales |
|
21,682 |
|
|
20,594 |
|
|
|
65,863 |
|
|
|
62,235 |
|
Research and development |
|
10,105 |
|
|
9,309 |
|
|
|
30,647 |
|
|
|
29,316 |
|
General and administrative |
|
17,058 |
|
|
16,477 |
|
|
|
49,713 |
|
|
|
49,770 |
|
Closure of |
|
22 |
|
|
1,194 |
|
|
|
186 |
|
|
|
6,388 |
|
Total operating expenses |
|
48,867 |
|
|
47,574 |
|
|
|
146,409 |
|
|
|
147,709 |
|
Income from operations |
|
10,415 |
|
|
6,058 |
|
|
|
19,772 |
|
|
|
19,149 |
|
Other income (loss), net |
|
320 |
|
|
(24 |
) |
|
|
(1,758 |
) |
|
|
(323 |
) |
Income before income taxes |
|
10,735 |
|
|
6,034 |
|
|
|
18,014 |
|
|
|
18,826 |
|
Provision for income taxes |
|
2,781 |
|
|
2,083 |
|
|
|
7,784 |
|
|
|
7,223 |
|
Net income |
$ |
7,954 |
|
$ |
3,951 |
|
|
$ |
10,230 |
|
|
$ |
11,603 |
|
|
|
|
|
|
|
|
|
|||||||
Net income per share: |
|
|
|
|
|
|
|
|||||||
Basic |
$ |
0.31 |
|
$ |
0.14 |
|
|
$ |
0.39 |
|
|
$ |
0.42 |
|
Diluted |
$ |
0.31 |
|
$ |
0.14 |
|
|
$ |
0.39 |
|
|
$ |
0.42 |
|
|
|
|
|
|
|
|
|
|||||||
Shares used to compute net income per share: |
|
|
|
|
|
|
|
|||||||
Basic |
|
26,023,830 |
|
|
27,505,097 |
|
|
|
26,296,304 |
|
|
|
27,512,057 |
|
Diluted |
|
26,028,456 |
|
|
27,508,217 |
|
|
|
26,327,606 |
|
|
|
27,522,734 |
|
|
|
|
|
|
|
|
|
Proto Labs, Inc. Condensed Consolidated Statements of Cash Flows (In thousands) (Unaudited) |
|||||||
|
|
|
|
||||
|
Nine Months Ended
|
||||||
|
|
2023 |
|
|
|
2022 |
|
Operating activities |
|
|
|
||||
Net income |
$ |
10,230 |
|
|
$ |
11,603 |
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
||||
Depreciation and amortization |
|
28,213 |
|
|
|
29,981 |
|
Stock-based compensation expense |
|
11,811 |
|
|
|
13,335 |
|
Deferred taxes |
|
(9,197 |
) |
|
|
(8,920 |
) |
Interest on finance lease obligations |
|
859 |
|
|
|
- |
|
Loss on foreign currency translation |
|
3,906 |
|
|
|
- |
|
Impairments related to closure of |
|
- |
|
|
|
2,842 |
|
Gain on disposal of property and equipment |
|
(498 |
) |
|
|
(1,174 |
) |
Other |
|
122 |
|
|
|
11 |
|
Changes in operating assets and liabilities: |
|
10,600 |
|
|
|
3,886 |
|
Net cash provided by operating activities |
|
56,046 |
|
|
|
51,564 |
|
|
|
|
|
||||
Investing activities |
|
|
|
||||
Purchases of property, equipment and other capital assets |
|
(9,935 |
) |
|
|
(16,414 |
) |
Proceeds from sales of property, equipment and other capital assets |
|
693 |
|
|
|
3,227 |
|
Purchases of marketable securities |
|
- |
|
|
|
(45,872 |
) |
Proceeds from sales of marketable securities |
|
- |
|
|
|
1,998 |
|
Proceeds from call redemptions and maturities of marketable securities |
|
19,115 |
|
|
|
13,696 |
|
Net cash provided by (used in) investing activities |
|
9,873 |
|
|
|
(43,365 |
) |
|
|
|
|
||||
Financing activities |
|
|
|
||||
Proceeds from exercises of stock options |
|
1,986 |
|
|
|
2,311 |
|
Purchases of shares withheld for tax obligations |
|
(1,436 |
) |
|
|
(1,615 |
) |
Repurchases of common stock |
|
(39,053 |
) |
|
|
(13,074 |
) |
Principal repayments of finance lease obligations |
|
(234 |
) |
|
|
(417 |
) |
Net cash used in financing activities |
|
(38,737 |
) |
|
|
(12,795 |
) |
Effect of exchange rate changes on cash and cash equivalents |
|
(244 |
) |
|
|
(1,972 |
) |
Net increase (decrease) in cash and cash equivalents |
|
26,938 |
|
|
|
(6,568 |
) |
Cash and cash equivalents, beginning of period |
|
56,558 |
|
|
|
65,929 |
|
Cash and cash equivalents, end of period |
$ |
83,496 |
|
|
$ |
59,361 |
|
|
|
|
|
Proto Labs, Inc. Reconciliation of GAAP to Non-GAAP Net Income per Share (In thousands, except share and per share amounts) (Unaudited) |
|||||||||||||||
|
|
|
|
|
|
|
|
||||||||
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
Non-GAAP net income, adjusted for stock-based compensation expense, amortization expense, unrealized (gain) loss on foreign currency and costs related to |
|
|
|
|
|
|
|
||||||||
GAAP net income |
$ |
7,954 |
|
|
$ |
3,951 |
|
|
$ |
10,230 |
|
|
$ |
11,603 |
|
Add back: |
|
|
|
|
|
|
|
||||||||
Stock-based compensation expense |
|
4,441 |
|
|
|
4,907 |
|
|
|
11,811 |
|
|
|
13,335 |
|
Amortization expense |
|
1,461 |
|
|
|
1,510 |
|
|
|
4,471 |
|
|
|
4,582 |
|
Unrealized (gain) loss on foreign currency |
|
(29 |
) |
|
|
382 |
|
|
|
86 |
|
|
|
742 |
|
Costs related to |
|
22 |
|
|
|
1,194 |
|
|
|
4,093 |
|
|
|
6,388 |
|
Total adjustments 1 |
|
5,895 |
|
|
|
7,993 |
|
|
|
20,461 |
|
|
|
25,047 |
|
Income tax benefits on adjustments 2 |
|
(633 |
) |
|
|
(1,060 |
) |
|
|
(931 |
) |
|
|
(2,518 |
) |
Non-GAAP net income |
$ |
13,216 |
|
|
$ |
10,884 |
|
|
$ |
29,760 |
|
|
$ |
34,132 |
|
|
|
|
|
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
||||||||
Non-GAAP net income per share: |
|
|
|
|
|
|
|
||||||||
Basic |
$ |
0.51 |
|
|
$ |
0.40 |
|
|
$ |
1.13 |
|
|
$ |
1.24 |
|
Diluted |
$ |
0.51 |
|
|
$ |
0.40 |
|
|
$ |
1.13 |
|
|
$ |
1.24 |
|
|
|
|
|
|
|
|
|
||||||||
Shares used to compute non-GAAP net income per share: |
|
|
|
|
|
|
|
||||||||
Basic |
|
26,023,830 |
|
|
|
27,505,097 |
|
|
|
26,296,304 |
|
|
|
27,512,057 |
|
Diluted |
|
26,028,456 |
|
|
|
27,508,217 |
|
|
|
26,327,606 |
|
|
|
27,522,734 |
|
|
|
|
|
|
|
|
1 |
Stock-based compensation expense, amortization expense, unrealized (gain) loss on foreign currency and costs related to |
|
Three Months Ended
|
|
Nine Months Ended
|
|||||||||
|
|
2023 |
|
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
|
|
|
|
|
|
|
|||||
Cost of revenue |
$ |
805 |
|
|
$ |
902 |
|
$ |
2,416 |
|
$ |
2,701 |
|
|
|
|
|
|
|
|
|||||
Marketing and sales |
|
961 |
|
|
|
929 |
|
|
2,508 |
|
|
2,479 |
Research and development |
|
675 |
|
|
|
602 |
|
|
1,888 |
|
|
1,702 |
General and administrative |
|
3,461 |
|
|
|
3,984 |
|
|
9,471 |
|
|
11,035 |
Closure of |
|
22 |
|
|
|
1,194 |
|
|
186 |
|
|
6,388 |
Total operating expenses |
|
5,119 |
|
|
|
6,709 |
|
|
14,053 |
|
|
21,604 |
|
|
|
|
|
|
|
|
|||||
Other income (loss), net |
|
(29 |
) |
|
|
382 |
|
|
3,992 |
|
|
742 |
Total adjustments |
$ |
5,895 |
|
|
$ |
7,993 |
|
$ |
20,461 |
|
$ |
25,047 |
2 |
For the three and nine months ended September 30, 2023 and 2022, income tax effects were calculated using the effective tax rate for the relevant jurisdictions. The Company's non-GAAP tax rates differ from its GAAP tax rates due primarily to the mix of activity incurred in domestic and foreign tax jurisdictions and removing effective tax rate benefits from stock-based compensation activity in the quarter. |
|
Proto Labs, Inc. Reconciliation of GAAP to Non-GAAP Gross Margin (In thousands) (Unaudited) |
|||||||||||||||
|
|
|
|
|
|
|
|
||||||||
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
Revenue |
$ |
130,705 |
|
|
$ |
121,721 |
|
|
$ |
378,829 |
|
|
$ |
372,791 |
|
Gross profit |
|
59,282 |
|
|
|
53,632 |
|
|
|
166,181 |
|
|
|
166,858 |
|
GAAP gross margin |
|
45.4 |
% |
|
|
44.1 |
% |
|
|
43.9 |
% |
|
|
44.8 |
% |
Add back: |
|
|
|
|
|
|
|
||||||||
Stock-based compensation expense |
|
462 |
|
|
|
560 |
|
|
|
1,388 |
|
|
|
1,674 |
|
Amortization expense |
|
343 |
|
|
|
342 |
|
|
|
1,028 |
|
|
|
1,027 |
|
Total adjustments |
|
805 |
|
|
|
902 |
|
|
|
2,416 |
|
|
|
2,701 |
|
Non-GAAP gross profit |
$ |
60,087 |
|
|
$ |
54,534 |
|
|
$ |
168,597 |
|
|
$ |
169,559 |
|
Non-GAAP gross margin |
|
46.0 |
% |
|
|
44.8 |
% |
|
|
44.5 |
% |
|
|
45.5 |
% |
|
|
|
|
|
|
|
|
Proto Labs, Inc. Reconciliation of GAAP to Non-GAAP Gross Margin Excluding Japan (In thousands) (Unaudited) |
|||||||||||||||
|
|
|
|
|
|
|
|
||||||||
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
Revenue |
$ |
130,705 |
|
|
$ |
121,721 |
|
|
$ |
378,829 |
|
|
$ |
372,791 |
|
Revenue excluding |
$ |
130,705 |
|
|
$ |
120,434 |
|
|
$ |
378,829 |
|
|
$ |
364,562 |
|
Gross profit |
|
59,282 |
|
|
|
53,632 |
|
|
|
166,181 |
|
|
|
166,858 |
|
GAAP gross margin |
|
45.4 |
% |
|
|
44.1 |
% |
|
|
43.9 |
% |
|
|
44.8 |
% |
Less: |
|
- |
|
|
|
47 |
|
|
|
- |
|
|
|
3,150 |
|
Gross Profit excluding |
|
59,282 |
|
|
|
53,585 |
|
|
|
166,181 |
|
|
|
163,708 |
|
GAAP gross margin excluding |
|
45.4 |
% |
|
|
44.5 |
% |
|
|
43.9 |
% |
|
|
44.9 |
% |
Add back: |
|
|
|
|
|
|
|
||||||||
Stock-based compensation expense |
|
462 |
|
|
|
560 |
|
|
|
1,388 |
|
|
|
1,674 |
|
Amortization expense |
|
343 |
|
|
|
342 |
|
|
|
1,028 |
|
|
|
1,027 |
|
Less: |
|
|
|
|
|
|
|
||||||||
|
|
- |
|
|
|
13 |
|
|
|
- |
|
|
|
61 |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
Total adjustments |
|
805 |
|
|
|
889 |
|
|
|
2,416 |
|
|
|
2,640 |
|
Non-GAAP gross profit excluding |
$ |
60,087 |
|
|
$ |
54,474 |
|
|
$ |
168,597 |
|
|
$ |
166,348 |
|
Non-GAAP gross margin excluding |
|
46.0 |
% |
|
|
45.2 |
% |
|
|
44.5 |
% |
|
|
45.6 |
% |
|
|
|
|
|
|
|
|
Proto Labs, Inc. Reconciliation of GAAP to Non-GAAP Operating Margin (In thousands) (Unaudited) |
|||||||||||||||
|
|
|
|
|
|
|
|
||||||||
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
Revenue |
$ |
130,705 |
|
|
$ |
121,721 |
|
|
$ |
378,829 |
|
|
$ |
372,791 |
|
Income from operations |
|
10,415 |
|
|
|
6,058 |
|
|
|
19,772 |
|
|
|
19,149 |
|
GAAP operating margin |
|
8.0 |
% |
|
|
5.0 |
% |
|
|
5.2 |
% |
|
|
5.1 |
% |
Add back: |
|
|
|
|
|
|
|
||||||||
Stock-based compensation expense |
|
4,441 |
|
|
|
4,907 |
|
|
|
11,811 |
|
|
|
13,335 |
|
Amortization expense |
|
1,461 |
|
|
|
1,510 |
|
|
|
4,471 |
|
|
|
4,582 |
|
Costs related to |
|
22 |
|
|
|
1,194 |
|
|
|
186 |
|
|
|
6,388 |
|
Total adjustments |
|
5,924 |
|
|
|
7,611 |
|
|
|
16,468 |
|
|
|
24,305 |
|
Non-GAAP income from operations |
$ |
16,339 |
|
|
$ |
13,669 |
|
|
$ |
36,240 |
|
|
$ |
43,454 |
|
Non-GAAP operating margin |
|
12.5 |
% |
|
|
11.2 |
% |
|
|
9.6 |
% |
|
|
11.7 |
% |
|
|
|
|
|
|
|
|
Proto Labs, Inc. Reconciliation of GAAP to Non-GAAP Operating Margin Excluding Japan (In thousands) (Unaudited) |
|||||||||||||||
|
|
|
|
|
|
|
|
||||||||
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
Revenue |
$ |
130,705 |
|
|
$ |
121,721 |
|
|
$ |
378,829 |
|
|
$ |
372,791 |
|
Revenue excluding |
$ |
130,705 |
|
|
$ |
120,434 |
|
|
$ |
378,829 |
|
|
$ |
364,562 |
|
Income from operations |
|
10,415 |
|
|
|
6,058 |
|
|
|
19,772 |
|
|
|
19,149 |
|
GAAP operating margin |
|
8.0 |
% |
|
|
5.0 |
% |
|
|
5.2 |
% |
|
|
5.1 |
% |
Less: |
|
(7 |
) |
|
|
(724 |
) |
|
|
(481 |
) |
|
|
(720 |
) |
Income from operations excluding |
|
10,422 |
|
|
|
6,782 |
|
|
|
20,253 |
|
|
|
19,869 |
|
GAAP operating margin excluding |
|
8.0 |
% |
|
|
5.6 |
% |
|
|
5.3 |
% |
|
|
5.5 |
% |
Add back: |
|
|
|
|
|
|
|
||||||||
Stock-based compensation expense |
|
4,441 |
|
|
|
4,907 |
|
|
|
11,811 |
|
|
|
13,335 |
|
Amortization expense |
|
1,461 |
|
|
|
1,510 |
|
|
|
4,471 |
|
|
|
4,582 |
|
Costs related to |
|
22 |
|
|
|
1,194 |
|
|
|
186 |
|
|
|
6,388 |
|
Less: |
|
|
|
|
|
|
|
||||||||
|
|
- |
|
|
|
89 |
|
|
|
17 |
|
|
|
386 |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
Total adjustments |
|
5,924 |
|
|
|
7,522 |
|
|
|
16,451 |
|
|
|
23,919 |
|
Non-GAAP income from operations excluding |
$ |
16,346 |
|
|
$ |
14,304 |
|
|
$ |
36,704 |
|
|
$ |
43,788 |
|
Non-GAAP operating margin excluding |
|
12.5 |
% |
|
|
11.9 |
% |
|
|
9.7 |
% |
|
|
12.0 |
% |
|
|
|
|
|
|
|
|
Proto Labs, Inc. Reconciliation of GAAP Net Income to EBITDA and Adjusted EBITDA (In thousands) (Unaudited) |
|||||||||||||||
|
|
|
|
|
|
|
|
||||||||
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
Revenue |
$ |
130,705 |
|
|
$ |
121,721 |
|
|
$ |
378,829 |
|
|
$ |
372,791 |
|
GAAP net income |
|
7,954 |
|
|
|
3,951 |
|
|
|
10,230 |
|
|
|
11,603 |
|
GAAP net income margin |
|
6.1 |
% |
|
|
3.2 |
% |
|
|
2.7 |
% |
|
|
3.1 |
% |
Add back: |
|
|
|
|
|
|
|
||||||||
Amortization expense |
$ |
1,461 |
|
|
$ |
1,510 |
|
|
$ |
4,471 |
|
|
$ |
4,582 |
|
Depreciation expense |
|
7,869 |
|
|
|
8,197 |
|
|
|
23,742 |
|
|
|
25,399 |
|
Interest income, net |
|
(561 |
) |
|
|
(265 |
) |
|
|
(1,283 |
) |
|
|
(459 |
) |
Provision for income taxes |
|
2,781 |
|
|
|
2,083 |
|
|
|
7,784 |
|
|
|
7,223 |
|
EBITDA |
|
19,504 |
|
|
|
15,476 |
|
|
|
44,944 |
|
|
|
48,348 |
|
EBITDA Margin |
|
14.9 |
% |
|
|
12.7 |
% |
|
|
11.9 |
% |
|
|
13.0 |
% |
Add back: |
|
|
|
|
|
|
|
||||||||
Stock-based compensation expense |
|
4,441 |
|
|
|
4,907 |
|
|
|
11,811 |
|
|
|
13,335 |
|
Unrealized (gain) loss on foreign currency |
|
(29 |
) |
|
|
382 |
|
|
|
86 |
|
|
|
742 |
|
Costs related to |
|
22 |
|
|
|
1,194 |
|
|
|
4,093 |
|
|
|
6,388 |
|
Total adjustments |
|
4,434 |
|
|
|
6,483 |
|
|
|
15,990 |
|
|
|
20,465 |
|
Adjusted EBITDA |
$ |
23,938 |
|
|
$ |
21,959 |
|
|
$ |
60,934 |
|
|
$ |
68,813 |
|
Adjusted EBITDA Margin |
|
18.3 |
% |
|
|
18.0 |
% |
|
|
16.1 |
% |
|
|
18.5 |
% |
|
|
|
|
|
|
|
|
Proto Labs, Inc. Comparison of GAAP to Non-GAAP Revenue Growth by Region (In thousands) (Unaudited) |
||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
Three Months Ended
|
|
Three Months Ended
|
|
% Change2 |
|
% Change Organic3 |
|||||||||||
|
GAAP |
|
Foreign Currency1 |
|
Non-GAAP |
|
GAAP |
|
|
|||||||||
Revenues |
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
$ |
103,940 |
|
$ |
- |
|
|
$ |
103,940 |
|
$ |
98,970 |
|
5.0 |
% |
|
5.0 |
% |
|
|
26,765 |
|
|
(1,666 |
) |
|
|
25,099 |
|
|
21,464 |
|
24.7 |
% |
|
16.9 |
% |
|
|
- |
|
|
- |
|
|
|
- |
|
|
1,287 |
|
(100.0 |
%) |
|
(100.0 |
%) |
Total revenue |
$ |
130,705 |
|
$ |
(1,666 |
) |
|
$ |
129,039 |
|
$ |
121,721 |
|
7.4 |
% |
|
6.0 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
Nine Months Ended
|
|
Nine Months Ended
|
|
% Change2 |
|
% Change Organic3 |
||||||||||
|
GAAP |
|
Foreign Currency1 |
|
Non-GAAP |
|
GAAP |
|
|
||||||||
Revenues |
|
|
|
|
|
|
|
|
|
|
|
||||||
|
$ |
298,007 |
|
$ |
- |
|
$ |
298,007 |
|
$ |
295,121 |
|
1.0 |
% |
|
1.0 |
% |
|
|
80,822 |
|
|
1,311 |
|
|
82,133 |
|
|
69,441 |
|
16.4 |
% |
|
18.3 |
% |
|
|
- |
|
|
- |
|
|
- |
|
|
8,229 |
|
(100.0 |
%) |
|
(100.0 |
%) |
Total revenue |
$ |
378,829 |
|
$ |
1,311 |
|
$ |
380,140 |
|
$ |
372,791 |
|
1.6 |
% |
|
2.0 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
1 |
Revenue for the three and nine months ended September 30, 2023 has been recalculated using 2022 foreign currency exchange rates in effect during comparable periods to provide information useful in evaluating the underlying business trends excluding the impact of changes in foreign currency exchange rates. |
2 |
This column presents the percentage change from GAAP revenue for the three and nine months ended September 30, 2022 to GAAP revenue for the three and nine months ended September 30, 2023. |
3 |
This column presents the percentage change from GAAP revenue for the three and nine months ended September 30, 2022 to non-GAAP revenue for the three and nine months ended September 30, 2023 (as recalculated using the foreign currency exchange rates in effect during the three and nine months ended September 30, 2022) in order to provide a constant-currency comparison. |
|
Proto Labs, Inc. Comparison of GAAP to Non-GAAP Revenue Growth by Service Line (In thousands) (Unaudited) |
||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
Three Months Ended
|
|
Three Months Ended September 30, 2022 |
|
% Change2 |
|
% Change Organic3 |
|||||||||||
|
GAAP |
|
Foreign Currency1 |
|
Non-GAAP |
|
GAAP |
|
|
|||||||||
Revenues |
|
|
|
|
|
|
|
|
|
|
|
|||||||
Injection Molding |
$ |
51,688 |
|
$ |
(655 |
) |
|
$ |
51,033 |
|
$ |
48,940 |
|
5.6 |
% |
|
4.3 |
% |
CNC Machining |
|
52,916 |
|
|
(708 |
) |
|
|
52,208 |
|
|
47,489 |
|
11.4 |
|
|
9.9 |
|
3D Printing |
|
21,622 |
|
|
(390 |
) |
|
|
21,232 |
|
|
19,823 |
|
9.1 |
|
|
7.1 |
|
Sheet Metal |
|
4,291 |
|
|
(20 |
) |
|
|
4,271 |
|
|
5,219 |
|
(17.8 |
) |
|
(18.2 |
) |
Other Revenue |
|
188 |
|
|
107 |
|
|
|
295 |
|
|
250 |
|
(24.8 |
) |
|
18.0 |
|
Total Revenue |
$ |
130,705 |
|
$ |
(1,666 |
) |
|
$ |
129,039 |
|
$ |
121,721 |
|
7.4 |
% |
|
6.0 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
Nine Months Ended
|
|
Nine Months Ended
|
|
% Change2 |
|
% Change Organic3 |
|||||||||||
|
GAAP |
|
Foreign Currency1 |
|
Non-GAAP |
|
GAAP |
|
|
|||||||||
Revenues |
|
|
|
|
|
|
|
|
|
|
|
|||||||
Injection Molding |
$ |
152,455 |
|
$ |
781 |
|
|
$ |
153,236 |
|
$ |
155,693 |
|
(2.1 |
)% |
|
(1.6 |
)% |
CNC Machining |
|
149,317 |
|
|
152 |
|
|
|
149,469 |
|
|
141,809 |
|
5.3 |
|
|
5.4 |
|
3D Printing |
|
63,952 |
|
|
277 |
|
|
|
64,229 |
|
|
59,458 |
|
7.6 |
|
|
8.0 |
|
Sheet Metal |
|
12,478 |
|
|
(9 |
) |
|
|
12,469 |
|
|
15,066 |
|
(17.2 |
) |
|
(17.2 |
) |
Other Revenue |
|
627 |
|
|
110 |
|
|
|
737 |
|
|
765 |
|
(18.0 |
) |
|
(3.7 |
) |
Total Revenue |
$ |
378,829 |
|
$ |
1,311 |
|
|
$ |
380,140 |
|
$ |
372,791 |
|
1.6 |
% |
|
2.0 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
1 |
Revenue for the three and nine months ended September 30, 2023 has been recalculated using 2022 foreign currency exchange rates in effect during comparable periods to provide information useful in evaluating the underlying business trends excluding the impact of changes in foreign currency exchange rates. |
|
|
2 |
This column presents the percentage change from GAAP revenue for the three and nine months ended September 30, 2022 to GAAP revenue for the three and nine months ended September 30, 2023. |
|
|
3 |
This column presents the percentage change from GAAP revenue for the three and nine months ended September 30, 2022 to non-GAAP revenue for the three and nine months ended September 30, 2023 (as recalculated using the foreign currency exchange rates in effect during the three and nine months ended September 30, 2022) in order to provide a constant-currency comparison. |
|
|
|
|
Proto Labs, Inc. Product Developer Information (Unaudited) |
|||||||
|
|
|
|
|
|
|
|
|
Three months ended September 30, |
|
Nine months ended September 30, |
||||
|
2023 |
|
2022 |
|
2023 |
|
2022 |
Unique product developers and engineers served |
23,080 |
|
23,816 |
|
45,668 |
|
47,793 |
|
|
|
|
|
|
|
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20231103037185/en/
Investor Relations Contact
Protolabs
Ryan Johnsrud, 612-225-4873
Manager – Investor Relations and FP&A
ryan.johnsrud@protolabs.com
Media Contact
Protolabs
Brent Renneke, 763-479-7704
PR & Media Strategist
brent.renneke@protolabs.com
Source: Proto Labs, Inc.
FAQ
What is the stock symbol of Proto Labs, Inc.?
What was the revenue in the third quarter of 2023?
What was the YoY increase in network revenue?
What were the GAAP and non-GAAP earnings per share?
What was the gross margin in the third quarter of 2023?
What was the EBITDA in the third quarter of 2023?
What was the cash flow from operations in the third quarter of 2023?